1. Home > Latest Topics >

Question 6: Mortality and morbidity rates

20 June, 2018

question_6_5


LATEST TOPICS

Navigating antibiotic resistance in community-acquired pneumonia: Insights from Vietnam
29 October, 2024
Optimising antibiotic therapy: Insights on transitioning from intravenous to oral treatment for community-acquired pneumonia
27 September, 2024
Community-acquired pneumonia in Cambodia: Navigating the growing challenge of AMR
30 June, 2024
Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024

RELATED ARTICLES

Levofloxacin in the Treatment of Hospital-Acquired Pneumonia: Insights into Antibiotic Resistance and Tolerance
18 October, 2023
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024
Colchicine does not prevent mechanical ventilation or reduce mortality risk in COVID-19 hospitalisations
25 March, 2022
Community-acquired pneumonia: Insights into the current challenges and the role of levofloxacin
29 January, 2024
Professional Insights: Navigating Optimal Diagnosis and Treatment of Infectious Diseases in the Emergency Department
05 February, 2024